Key result
Transcatheter mitral valve edge-to-edge repair with MitraClip significantly reduced 3-year all-cause mortality to 12.9% compared to 45.0% with medical therapy in high surgical-risk patients with severe mitral regurgitation.
Why the study?
Long-term outcomes of transcatheter mitral valve edge-to-edge repair compared with medical therapy remain under investigation.
Does transcatheter mitral valve edge-to-edge repair (TEER) improve mitral regurgitation severity, ventricular remodeling, and clinical outcomes in high surgical-risk patients compared to medical therapy?
Cohort (n=61)
No
Does transcatheter mitral valve edge-to-edge repair (TEER) improve mitral regurgitation severity, ventricular remodeling, and clinical outcomes in high surgical-risk patients compared to medical therapy?
Absolute Event Rate: 12.9% vs 45%
p-value: p=0.007
In high surgical-risk patients with mitral regurgitation, TEER provides durable MR reduction, improved functional capacity, and significant survival benefits at 3 years compared to medical therapy alone.
May support TEER evaluation in high-risk MR; hypothesis-generating and requires RCTs before practice change.
BACKGROUND: Long-term outcomes of transcatheter mitral valve edge-to-edge repair (TEER) are compared with medical therapy remain under investigation. This study evaluated the 3-year effects of MitraClip on mitral regurgitation (MR) severity, ventricular remodeling, and clinical outcomes in high surgical-risk patients. METHODS: A single-center retrospective cohort included 31 MitraClip patients (2016-2023) and 30 contemporaneous controls on maximally tolerated guideline-directed medical therapy. Anatomical suitability was based on EVEREST criteria. Echocardiography was performed at baseline, 1, 2, and 3 years. Outcomes included MR severity, left ventricular ejection fraction (LVEF), right-sided parameters, biomarkers, NYHA class, 6-min walk test, heart failure (HF) hospitalizations, and all-cause mortality. RESULTS: Mean age was 63.2 ± 14.5 MitraClip vs. 72.1 ± 8.9 years controls, with secondary MR in 61.3% vs. 56.7%. Severe pulmonary hypertension (SPAP > 50 mmHg) was present in 25% of primary and 55% of secondary MR patients. No procedural mortality occurred. MR improved significantly with MitraClip (93.0% mild to moderate at 1st year, 83.9% at 3rd year) while controls remained severe (p < 0.001). LVEF remained stable (~ 33-35%, p = 0.412) without correlation to MR reduction. HF hospitalizations were lower with MitraClip (58.1%, 2.1 ± 1.8 admissions) vs. controls (7.6 ± 3.2, p < 0.001). Within MitraClip, secondary MR patients had higher rates (68.4% vs. 41.7%, p = 0.042). SPAP decreased after MitraClip but rose in controls (p = 0.015). BNP declined with MitraClip but increased in controls (p = 0.01). At 3 years, more MitraClip patients were in NYHA I/II (41.9% vs. 15%), 6MWT improved while controls declined, and mortality was lower (12.9% vs. 45%, p < 0.01). CONCLUSION: TEER provides durable MR reduction, BNP stabilization, improved functional capacity, and survival benefits compared with medical therapy in high-risk surgical patients. Primary MR patients might derive greater benefit than those with secondary MR. Larger multicenter studies are warranted.
No takes yet. Share an insight, caveat, or question.
AlRahimi et al. (2025) conducted a cohort in Severe symptomatic mitral regurgitation (n=61). Transcatheter mitral valve edge-to-edge repair (MitraClip) vs. Maximally tolerated guideline-directed medical therapy (GDMT) was evaluated on All-cause mortality at 3 years (p=0.007). Transcatheter mitral valve edge-to-edge repair with MitraClip significantly reduced 3-year all-cause mortality to 12.9% compared to 45.0% with medical therapy in high surgical-risk patients with severe mitral regurgitation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: